Page 151 - 80_01
P. 151
Luis
García--Sevillano
65.
Kay,
J.;
Upchurch,
K.
S.
ACR/EULAR
2010
rheumatoid
arthritis
classification
criteria.
Rheumatology
(Oxford)
51
(Suppl6),
vi5--vi9
(2012).
Disponible
en
http://dx.doi.org/10.1093/rheumatology/kes279.
66.
Van
der
Linden,
M.P.;
Batstra,
M.R.;
Bakker--Jonges,
L.E.;
Detert,
J.;
Bastian,
H.;
Scherer,
H.U.;
et
al.
Toward
a
data--driven
evaluation
of
the
2010
American
College
of
Rheumatology
/
European
League
Against
Rheumatism
criteria
for
rheumatoid
arthritis:
is
it
sensible
to
look
at
levels
of
rheumatoid
factor?
Arthritis
Rheum
63,
1190--1199
(2011).
67.
Humphreys,
J.H.;
Symmons,
D.P.
Postpublication
validation
of
the
2010
American
College
of
Rheumatology/European
League
Against
Rheumatism
classification
criteria
for
rheumatoid
arthritis:
where
do
we
stand?
Curr
Opin
Rheumatol
25,
157--163
(2013).
68.
Hulsemann,
J.
L.;
Zeidler,
H.
Undifferentiated
arthritis
in
an
early
synovitis
out--patient
clinic.
Clin
Exp
Rheumatol
13,
37--43,
(1995).
69.
Mochan
E,
Ebell
M.
H.
Predicting
rheumatoid
arthritis
risk
in
adults
with
undifferentiated
arthritis.
Am
Fam
Physician
77,
1451--1453
(2008).
70.
Lamana,
A.;
Balsa,
A.;
Rueda,
B.;
Ortiz,
A.
M.;
Nuño,
L.;
Miranda--Carus,
M.
A.;
et
al.
The
TT
Genotype
of
the
STAT4
rs7574865
Polymorphism
Is
Associated
with
High
Disease
Activity
and
Disability
in
Patients
with
Early
Arthritis.
PLoS
ONE
7,
e43661
(2012).
Disponible
en
http://dx.doi.org/10.1371/journal.pone.0043661
71.
Balsa
A,
Cabezón
A,
Orozco
G,
Cobo,
T.;
Miranda--Carus,
E.;
López--Nevot,
M.
A.;
et
al.
Influence
of
HLA
DRB1
alleles
in
the
susceptibility
of
rheumatoid
arthritis
and
the
regulation
of
antibodies
against
citrullinated
proteins
and
rheumatoid
factor.
Arthritis
Res
Ther
12,
R62
(2010).
Disponible
en:
http://arthritis--research.com/content/12/2/R62
72.
Lundberg,
K.;
Bengtsson,
C.;Kharlamova,
N.;Reed,
E.;Jiang,
X.;Kallberg,
H.;
et
al.
Genetic
and
environmental
determinants
for
disease
risk
in
subsets
of
rheumatoid
arthritis
defined
by
the
anticitrullinated
protein/peptide
antibody
fine
specificity
profile.
Ann
Rheum
Dis
72,
652--658
(2013).
Disponible
en:
http://dx.doi.org/10.1136/annrheumdis--2012--201484
73.
Ravelli,
A.;
Felici,
E.;
Magni--Manzoni,
S.;
Pistorio,
A.;
Novarini,
C.;
Bozzola,
E.;
et
al.
Patients
with
antinuclear
antibody--positive
juvenile
idiopathic
arthritis
constitute
a
homogeneous
subgroup
irrespective
of
the
course
of
joint
disease.
Arthritis
Rheum
52,
826--832
(2005).
74.
Yuasa,
S.;
Yamaguchi,
H.;
Nakanishi,
Y.;
Kawaminami,
S.;
Tabata,
R.;
Shimizu,
N.;
et
al.
Treatment
responses
and
their
predictors
in
patients
with
rheumatoid
arthritis
treated
with
biological
agents.
J
Med
Invest
60,
77--90
(2013).
75.
Willemze,
A.;Toes,
R.
E.;Huizinga,
T.
W.;Trouw,
L.
A.New
biomarkers
in
rheumatoid
arthritis.
Neth
J
Med
70,
392--399
(2012).
76.
Disponible
en:
http://www.omeract.org/
77.
Welsing,
P.
M.;
van
Gestel,
A.
M.;
Swinkels,
H.
L.;
Kiemeney,
L.
A.;
van
Riel,
P.L.
The
relationship
between
disease
activity,
joint
destruction,
and
functional
capacity
over
the
course
of
rheumatoid
arthritis.
Arthritis
Rheum
44,
2009--2017
(2001).
78.
Anderson,
J.K.;
Zimmerman,
L.;
Caplan,
L.
;
Michaud,
K.
Measures
of
rheumatoid
arthritis
disease
activity:
Patient
(PtGA)
and
Provider
(PrGA)
Global
Assessment
of
Disease
Activity,
Disease
Activity
Score
(DAS)
and
Disease
Activity
Score
with
28--Joint
Counts
(DAS28),
Simplified
Disease
Activity
Index
(SDAI),
Clinical
Disease
Activity
Index
(CDAI),
Patient
Activity
Score
(PAS)
and
Patient
Activity
Score--II
(PASII),
Routine
Assessment
of
Patient
Index
Data
(RAPID),
Rheumatoid
Arthritis
Disease
Activity
Index
(RADAI)
and
Rheumatoid
Arthritis
Disease
Activity
Index--5
(RADAI--5),
Chronic
Arthritis
Systemic
Index
(CASI),
Patient--Based
Disease
Activity
Score
With
ESR
(PDAS1)
and
Patient--Based
Disease
Activity
Score
without
ESR
(PDAS2),
and
Mean
Overall
Index
for
Rheumatoid
Arthritis
(MOI--RA).Arthritis
Care
Res
63(Suppl
11),
S14--36
(2011).
79.
Prevoo,
M.L.;
van
't
Hof,
M.A.;
Kuper,
H.H.;
van
Leeuwen,
M.A.;
van
de
Putte,
L.B.;van
Riel,
P.L.
Modified
disease
activity
scores
that
include
twenty--eight--joint
counts.
Development
and
validation
in
a
prospective
longitudinal
study
of
patients
with
rheumatoid
arthritis.Arthritis
Rheum
38,
44--48
(1995).
80.
Hochberg,
M.
C.;
Chang,
R.
W.;
Dwosh,
I.;
Lindsey,
S.;
Pincus,
T.;
Wolfe
F.
The
AmericanCollege
of
Rheumatology
1991
revised
criteria
for
the
classification
of
global
functional
status
in
rheumatoid
arthritis.
Arthritis
Rheum
35,
498--502
(1992).
81.
Emery,
P.;
Breedveld,
F.C.;
Hall,
S.;
Durez,
P.;
Chang,
D.J.;
Robertson,
D.;
et
al.
Comparison
of
methotrexate
monotherapy
with
a
combination
of
methotrexate
and
etanercept
in
active,
early,
moderate
to
severe
rheumatoid
arthritis
(COMET):
a
randomised,
double--blind,
parallel
treatment
trial.
Lancet
372,
375--382
(2008).
148
